In agreement, several previous studies reported that anti-TNF-α therapy is helpful to inhibit the development of steatohepatitis in patients with severe alcoholic steatohepatitis and nonalcoholic fatty liver disease in rodents and humans [30,31]. The gene discussed is TNF; the disease is metabolic dysfunction-associated steatotic liver disease.